Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTC interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study
Domperidone, ondansetron and olanzapine can prolong the QT interval. The clinical use of combinations of these drugs is not uncommon. Our study aimed to determine the presence of any QTc prolonging effect of the combination when used as antiemetic in patients receiving cancer chemotherapy. We carrie...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2021-01, Vol.11 (1), p.445-445, Article 445 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 445 |
|---|---|
| container_issue | 1 |
| container_start_page | 445 |
| container_title | Scientific reports |
| container_volume | 11 |
| creator | Kamath, Ashwin Rai, K. Maneesh Shreyas, R. Saxena, PU Prakash Banerjee, Sourjya |
| description | Domperidone, ondansetron and olanzapine can prolong the QT interval. The clinical use of combinations of these drugs is not uncommon. Our study aimed to determine the presence of any QTc prolonging effect of the combination when used as antiemetic in patients receiving cancer chemotherapy. We carried out a prospective, observational study of patients with malignancy who were to receive domperidone, ondansetron and olanzapine-containing antiemetic regimen. Electrocardiograms were recorded before and during the administration of antiemetics, for three consecutive days. A blinded assessor determined the QTc interval using Bazett and Fridericia formulae. Thirty-six patients completed the study; 23 (63.9%) were females. There was a statistically significant change in QTc with time (Fridericia, χ
2
(4) = 15.629,
p
= 0.004; Bazett, χ
2
(4) = 15.910,
p
= 0.003); QTc on Day 1 was more than that during baseline (
p
500 ms. However, no clinically significant adverse events occurred. The findings show that QTc prolongation is a concern with olanzapine alone and in combination with domperidone and ondansetron, and needs to be investigated further. |
| doi_str_mv | 10.1038/s41598-020-79380-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_proquest_journals_2476744930</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_22863393271245d3999513d2007e8060</doaj_id><sourcerecordid>2477265250</sourcerecordid><originalsourceid>FETCH-LOGICAL-c517t-c5574853f79a2e1f444f0bd89d792982654153fdd69eab1b02edbeb7bc344c103</originalsourceid><addsrcrecordid>eNp9Uk1v1DAQjRCIVqV_gJMlLhw24K-sYw5IaFWgUiWEVM6WE09SrxI72M5Wy2_jx-FsKqAc8MEe2--9sd9MUbwk-A3BrH4bOalkXWKKSyFZjUvypDinmFclZZQ-_Ss-Ky5j3OM8Kio5kc-LM8Y4I1JW58XPq66DNiHfIePHCYI13sEGeWe0i5CCd3kzaPdDT9ZB2XqXtHXW9Ui7ZGGEZFsUoLcjuMxCX293yLoE4aCHHKBJZ5RLEd3bdIdGPdjeadce3yGNpuDjlLPbw5KxiQspWe_0sEExpxig7IOfpw3SMUKMPpTNYJ0Bg2KazfFF8azTQ4TLh_Wi-Pbx6nb3ubz58ul69-GmbCsiUp4rweuKdUJqCqTjnHe4MbU0QlJZ022VvWSdMVsJuiENpmAaaETTMs7b7PZFcb3qGq_3agp21OGovLbqdOBDr3TIPgygKK23jElGBaG8MkxmlwkzFGMBNd4uWu9XrWluRjBt9ibo4ZHo4xtn71TvD0rUmDBZZYHXDwLBf58hJjXa2MKQawR-jopyIfKXaLXkevUPdO_nkO09obaCc8kWFF1RbS5HDND9fgzBauk1tfaayr2mTr2mSCaxlRQz2PUQ_kj_h_ULxFzYuA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2476744930</pqid></control><display><type>article</type><title>Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTC interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study</title><source>Nature Open Access</source><source>Springer Open Access</source><source>EZB Free E-Journals</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Kamath, Ashwin ; Rai, K. Maneesh ; Shreyas, R. ; Saxena, PU Prakash ; Banerjee, Sourjya</creator><creatorcontrib>Kamath, Ashwin ; Rai, K. Maneesh ; Shreyas, R. ; Saxena, PU Prakash ; Banerjee, Sourjya</creatorcontrib><description>Domperidone, ondansetron and olanzapine can prolong the QT interval. The clinical use of combinations of these drugs is not uncommon. Our study aimed to determine the presence of any QTc prolonging effect of the combination when used as antiemetic in patients receiving cancer chemotherapy. We carried out a prospective, observational study of patients with malignancy who were to receive domperidone, ondansetron and olanzapine-containing antiemetic regimen. Electrocardiograms were recorded before and during the administration of antiemetics, for three consecutive days. A blinded assessor determined the QTc interval using Bazett and Fridericia formulae. Thirty-six patients completed the study; 23 (63.9%) were females. There was a statistically significant change in QTc with time (Fridericia, χ
2
(4) = 15.629,
p
= 0.004; Bazett, χ
2
(4) = 15.910,
p
= 0.003); QTc on Day 1 was more than that during baseline (
p
< 0.001); these differences were significant in females (Fridericia, χ
2
(4) = 13.753,
p
= 0.008; Bazett, χ
2
(4) = 13.278,
p
= 0.010) but not in males (Fridericia, χ
2
(4) = 4.419,
p
= 0.352; Bazett, χ
2
(4) = 4.280,
p
= 0.369). Two female patients had an absolute QTc prolongation (Bazett correction) of > 500 ms. However, no clinically significant adverse events occurred. The findings show that QTc prolongation is a concern with olanzapine alone and in combination with domperidone and ondansetron, and needs to be investigated further.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-020-79380-1</identifier><identifier>PMID: 33431995</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/4019 ; 692/4028 ; Adverse events ; Antiemetics ; Antipsychotics ; Cancer therapies ; Chemotherapy ; Drug dosages ; Drug interactions ; Electrocardiography ; Heart rate ; Higher education ; Humanities and Social Sciences ; Malignancy ; Medical schools ; multidisciplinary ; Nausea ; Observational studies ; Olanzapine ; Oncology ; Radiation ; Science ; Science (multidisciplinary) ; Statistical analysis ; Vomiting</subject><ispartof>Scientific reports, 2021-01, Vol.11 (1), p.445-445, Article 445</ispartof><rights>The Author(s) 2021</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c517t-c5574853f79a2e1f444f0bd89d792982654153fdd69eab1b02edbeb7bc344c103</citedby><cites>FETCH-LOGICAL-c517t-c5574853f79a2e1f444f0bd89d792982654153fdd69eab1b02edbeb7bc344c103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801395/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801395/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,27901,27902,41096,42165,51551,53766,53768</link.rule.ids></links><search><creatorcontrib>Kamath, Ashwin</creatorcontrib><creatorcontrib>Rai, K. Maneesh</creatorcontrib><creatorcontrib>Shreyas, R.</creatorcontrib><creatorcontrib>Saxena, PU Prakash</creatorcontrib><creatorcontrib>Banerjee, Sourjya</creatorcontrib><title>Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTC interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><description>Domperidone, ondansetron and olanzapine can prolong the QT interval. The clinical use of combinations of these drugs is not uncommon. Our study aimed to determine the presence of any QTc prolonging effect of the combination when used as antiemetic in patients receiving cancer chemotherapy. We carried out a prospective, observational study of patients with malignancy who were to receive domperidone, ondansetron and olanzapine-containing antiemetic regimen. Electrocardiograms were recorded before and during the administration of antiemetics, for three consecutive days. A blinded assessor determined the QTc interval using Bazett and Fridericia formulae. Thirty-six patients completed the study; 23 (63.9%) were females. There was a statistically significant change in QTc with time (Fridericia, χ
2
(4) = 15.629,
p
= 0.004; Bazett, χ
2
(4) = 15.910,
p
= 0.003); QTc on Day 1 was more than that during baseline (
p
< 0.001); these differences were significant in females (Fridericia, χ
2
(4) = 13.753,
p
= 0.008; Bazett, χ
2
(4) = 13.278,
p
= 0.010) but not in males (Fridericia, χ
2
(4) = 4.419,
p
= 0.352; Bazett, χ
2
(4) = 4.280,
p
= 0.369). Two female patients had an absolute QTc prolongation (Bazett correction) of > 500 ms. However, no clinically significant adverse events occurred. The findings show that QTc prolongation is a concern with olanzapine alone and in combination with domperidone and ondansetron, and needs to be investigated further.</description><subject>692/4019</subject><subject>692/4028</subject><subject>Adverse events</subject><subject>Antiemetics</subject><subject>Antipsychotics</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Drug dosages</subject><subject>Drug interactions</subject><subject>Electrocardiography</subject><subject>Heart rate</subject><subject>Higher education</subject><subject>Humanities and Social Sciences</subject><subject>Malignancy</subject><subject>Medical schools</subject><subject>multidisciplinary</subject><subject>Nausea</subject><subject>Observational studies</subject><subject>Olanzapine</subject><subject>Oncology</subject><subject>Radiation</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Statistical analysis</subject><subject>Vomiting</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNp9Uk1v1DAQjRCIVqV_gJMlLhw24K-sYw5IaFWgUiWEVM6WE09SrxI72M5Wy2_jx-FsKqAc8MEe2--9sd9MUbwk-A3BrH4bOalkXWKKSyFZjUvypDinmFclZZQ-_Ss-Ky5j3OM8Kio5kc-LM8Y4I1JW58XPq66DNiHfIePHCYI13sEGeWe0i5CCd3kzaPdDT9ZB2XqXtHXW9Ui7ZGGEZFsUoLcjuMxCX293yLoE4aCHHKBJZ5RLEd3bdIdGPdjeadce3yGNpuDjlLPbw5KxiQspWe_0sEExpxig7IOfpw3SMUKMPpTNYJ0Bg2KazfFF8azTQ4TLh_Wi-Pbx6nb3ubz58ul69-GmbCsiUp4rweuKdUJqCqTjnHe4MbU0QlJZ022VvWSdMVsJuiENpmAaaETTMs7b7PZFcb3qGq_3agp21OGovLbqdOBDr3TIPgygKK23jElGBaG8MkxmlwkzFGMBNd4uWu9XrWluRjBt9ibo4ZHo4xtn71TvD0rUmDBZZYHXDwLBf58hJjXa2MKQawR-jopyIfKXaLXkevUPdO_nkO09obaCc8kWFF1RbS5HDND9fgzBauk1tfaayr2mTr2mSCaxlRQz2PUQ_kj_h_ULxFzYuA</recordid><startdate>20210111</startdate><enddate>20210111</enddate><creator>Kamath, Ashwin</creator><creator>Rai, K. Maneesh</creator><creator>Shreyas, R.</creator><creator>Saxena, PU Prakash</creator><creator>Banerjee, Sourjya</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210111</creationdate><title>Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTC interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study</title><author>Kamath, Ashwin ; Rai, K. Maneesh ; Shreyas, R. ; Saxena, PU Prakash ; Banerjee, Sourjya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c517t-c5574853f79a2e1f444f0bd89d792982654153fdd69eab1b02edbeb7bc344c103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>692/4019</topic><topic>692/4028</topic><topic>Adverse events</topic><topic>Antiemetics</topic><topic>Antipsychotics</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Drug dosages</topic><topic>Drug interactions</topic><topic>Electrocardiography</topic><topic>Heart rate</topic><topic>Higher education</topic><topic>Humanities and Social Sciences</topic><topic>Malignancy</topic><topic>Medical schools</topic><topic>multidisciplinary</topic><topic>Nausea</topic><topic>Observational studies</topic><topic>Olanzapine</topic><topic>Oncology</topic><topic>Radiation</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Statistical analysis</topic><topic>Vomiting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kamath, Ashwin</creatorcontrib><creatorcontrib>Rai, K. Maneesh</creatorcontrib><creatorcontrib>Shreyas, R.</creatorcontrib><creatorcontrib>Saxena, PU Prakash</creatorcontrib><creatorcontrib>Banerjee, Sourjya</creatorcontrib><collection>Springer Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kamath, Ashwin</au><au>Rai, K. Maneesh</au><au>Shreyas, R.</au><au>Saxena, PU Prakash</au><au>Banerjee, Sourjya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTC interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><date>2021-01-11</date><risdate>2021</risdate><volume>11</volume><issue>1</issue><spage>445</spage><epage>445</epage><pages>445-445</pages><artnum>445</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Domperidone, ondansetron and olanzapine can prolong the QT interval. The clinical use of combinations of these drugs is not uncommon. Our study aimed to determine the presence of any QTc prolonging effect of the combination when used as antiemetic in patients receiving cancer chemotherapy. We carried out a prospective, observational study of patients with malignancy who were to receive domperidone, ondansetron and olanzapine-containing antiemetic regimen. Electrocardiograms were recorded before and during the administration of antiemetics, for three consecutive days. A blinded assessor determined the QTc interval using Bazett and Fridericia formulae. Thirty-six patients completed the study; 23 (63.9%) were females. There was a statistically significant change in QTc with time (Fridericia, χ
2
(4) = 15.629,
p
= 0.004; Bazett, χ
2
(4) = 15.910,
p
= 0.003); QTc on Day 1 was more than that during baseline (
p
< 0.001); these differences were significant in females (Fridericia, χ
2
(4) = 13.753,
p
= 0.008; Bazett, χ
2
(4) = 13.278,
p
= 0.010) but not in males (Fridericia, χ
2
(4) = 4.419,
p
= 0.352; Bazett, χ
2
(4) = 4.280,
p
= 0.369). Two female patients had an absolute QTc prolongation (Bazett correction) of > 500 ms. However, no clinically significant adverse events occurred. The findings show that QTc prolongation is a concern with olanzapine alone and in combination with domperidone and ondansetron, and needs to be investigated further.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33431995</pmid><doi>10.1038/s41598-020-79380-1</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2021-01, Vol.11 (1), p.445-445, Article 445 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_proquest_journals_2476744930 |
| source | Nature Open Access; Springer Open Access; EZB Free E-Journals; DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | 692/4019 692/4028 Adverse events Antiemetics Antipsychotics Cancer therapies Chemotherapy Drug dosages Drug interactions Electrocardiography Heart rate Higher education Humanities and Social Sciences Malignancy Medical schools multidisciplinary Nausea Observational studies Olanzapine Oncology Radiation Science Science (multidisciplinary) Statistical analysis Vomiting |
| title | Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTC interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T14%3A17%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20domperidone,%20ondansetron,%20olanzapine-containing%20antiemetic%20regimen%20on%20QTC%20interval%20in%20patients%20with%20malignancy:%20a%20prospective,%20observational,%20single-group,%20assessor-blinded%20study&rft.jtitle=Scientific%20reports&rft.au=Kamath,%20Ashwin&rft.date=2021-01-11&rft.volume=11&rft.issue=1&rft.spage=445&rft.epage=445&rft.pages=445-445&rft.artnum=445&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-020-79380-1&rft_dat=%3Cproquest_doaj_%3E2477265250%3C/proquest_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2476744930&rft_id=info:pmid/33431995&rft_doaj_id=oai_doaj_org_article_22863393271245d3999513d2007e8060&rfr_iscdi=true |